Meeting report: ISN forefronts in nephrology on endothelial biology and renal disease: From bench to prevention

Kidney International

Volumn 70, Issue 2, 2006, Pages 258-264

  Goligorsky, M S ^a,b   Rabelink, T ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Carbon monoxide; Epoxides; Nitric oxide; Senescence; Stem and progenitor cells

Indexed keywords

BIOLOGICAL MARKER; CARBON MONOXIDE; EPOXIDE; HEME OXYGENASE 1; NITRIC OXIDE SYNTHASE; RHO KINASE; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

APOPTOSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME REGULATION; EPIGENETICS; HUMAN; HYPOXIA; MONOCYTE; NEPHROLOGY; NITROSYLATION; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; SCIENTIST; SHEAR STRESS; SMOOTH MUSCLE FIBER; THROMBOCYTE;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY;

EID: 33746164758     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001559     Document Type: Conference Paper

References (89)

1. Oliver JA, Maarouf O, Cheema FH et al. The renal papilla is a niche for adult kidney stem cells. J Clin Invest 2004; 114: 795-804.
2. Oliver JA, Barasch J, Yang J et al. Metanephric mesenchyme contains embryonic renal stem cells. Am J Physiol Renal Physiol 2002; 283: F799-809.
3. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
4. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic actors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
5. Karumanchi SA, Maynard SE, Stillman IE et al. Preeclampsia: a renal perspective. Kidney Int 2005; 67: 2101-2113.
6. Wolf M, Hubel CA, Lam C et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004; 89: 6239-6243.
7. Bedell VM, Yeo SY, Park KW et al. Roundabout4 is essential for angiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 6373-6378.
8. Chan B, Sinha S, Cho D et al. Critical roles of CD146 in zebrafish vascular development. Dev Dyn 2005; 232: 232-244.
9. Parikh SM, Mammoto T, Schultz A et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3: e46.
10. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and asculogenesis. Arterioscler Thromb Vasc Biol 2006; 26: 716-728.
11. van Nieuw Amerongen GP, van Hinsbergh VW. Targets for pharmacological intervention of endothelial hyperpermeability and barrier function. Vas Pharmacol 2002; 39: 257-272.
12. van Hinsbergh VW, van Nieuw Amerongen GP. Endothelial hyperpermeability in vascular leakage. Vas Pharmacol 2002; 39: 171-172.
13. Leiper JM, Vallance P. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 2006; 62: 33-38.
14. Smith CL, Anthony S, Hubank M et al. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS Med 2005; 2: e264.
15. Smith CL, Vallance P. Cardiovascular tests: use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disorders. Curr Pharm Des 2005; 11: 2177-2185.
16. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1023-1030.
17. Haendeler J, Tischler V, Hoffmann J et al. Low doses of reactive oxygen species protect endothelial cells from apoptosis by increasing thioredoxin-1 expression. FEBS Lett 2004; 577: 427-433.
18. Haendeler J, Hoffmann J, Diehl JF et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res 2004; 94: 768-775.
19. Yamawaki H, Haendeler J, Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res 2003; 93: 1029-1033.
20. Tai LK, Zheng Q, Pan S et al. Flow activates ERK1/2 and endothelial nitric oxide synthase via a pathway involving PECAM1, SHP2, and Tie2. J Biol Chem 2005; 280: 29620-29624.
21. Yamawaki H, Pan S, Lee RT, Berk BC. Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest 2005; 115: 733-738.
22. Yamawaki H, Berk BC. Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr Opin Nephrol Hypertens 2005; 14: 149-153.
23. Wolin MS, Ahmad M, Gupte SA. Oxidant and redox signaling in vascular oxygen sensing mechanisms: basic concepts, current controversies, and potential importance of cytosolic NADPH. Am J Physiol Lung Cell Mol Physiol 2005; 289: L159-L173.
24. Wolin MS, Ahmad M, Gupte SA. The sources of oxidative stress in the vessel wall. Kidney Int 2005; 67: 1659-1661.
25. Kinugawa S, Zhang J, Messina E et al. gp91phox-containing NAD(P)H oxidase mediates attenuation of nitric oxide-dependent control of myocardial oxygen consumption by ANG II. Am J Physiol Heart Circ Physiol 2005; 289: H862-H867.
26. Kinugawa S, Huang H, Wang Z et al. A defect of neuronal nitric oxide synthase increases xanthine oxidase-derived superoxide anion and attenuates the control of myocardial oxygen consumption by nitric oxide derived from endothelial nitric oxide synthase. Circ Res 2005; 96: 355-362.
27. Ojaimi C, Li W, Kinugawa S et al. Transcriptional basis for exercise limitation in male eNOS-knockout mice with age: heart failure and the fetal phenotype. Am J Physiol Heart Circ Physiol 2005; 289: H1399-H1407.
28. Kinugawa S, Wang Z, Kaminski PM et al. Limited exercise capacity in heterozygous manganese superoxide dismutase gene-knockout mice: roles of superoxide anion and nitric oxide. Circulation 2005; 111: 1480-1486.
29. Fish JE, Matouk CC, Rachlis A et al. The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code. J Biol Chem 2005; 280: 24824-24838.
30. Chan Y, Fish JE, D'Abreo C et al. The cell-specific expression of endothelial nitric-oxide synthase: a role for DNA methylation. J Biol Chem 2004; 279: 35087-35100.
31. Hao G, Derakhshan B, Shi L et al. SNOSID, a proteomic method for identification of cysteine S-nitrosylation sites in complex protein mixtures. Proc Natl Acad Sci USA 2006; 103: 1012-1017.
32. Mukai Y, Rikitake Y, Shiojima I et al. Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest 2006; 116: 334-343.
33. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-1235.
34. Rikitake Y, Kim HH, Huang Z et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36: 2251-2257.
35. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33F.
36. Bernhardt WM, Schmitt R, Rosenberger C et al. Expression of hypoxia-inducible transcription factors in developing human and rat kidneys. Kidney Int 2006; 69: 114-122.
37. Eckardt KU, Bernhardt WM, Weidemann A et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl 2005; 99: S46-S51.
38. Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest 2005; 35(Suppl 3): 13-19.
39. Williams TM, Lisanti MP. The caveolin genes: from cell biology to medicine. Ann Med 2004; 36: 584-595.
40. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84: 1341-1379.
41. Bernatchez PN, Bauer PM, Yu J et al. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci USA 2005; 102: 761-766.
42. Bauer PM, Yu J, Chen Y et al. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc Natl Acad Sci USA 2005; 102: 204-209.
43. Gratton JP, Bernatchez P, Sessa WC. Caveolae and caveolins in the cardiovascular system. Circ Res 2004; 94: 1408-1417.
44. Yu J, DeMuinck ED, Zhuang Z et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci USA 2005; 102: 10999-11004.
45. Nieuwdorp M, van Haeften TW, Gouverneur MC et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006; 55: 480-486.
46. Nieuwdorp M, Meuwese MC, Vink H et al. The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol 2005; 16: 507-511.
47. Shu L, Murphy HS, Cooling L, Shayman JA. An in vitro model of Fabry disease. J Am Soc Nephrol 2005; 16: 2636-2645.
48. Bodary PF, Shen Y, Vargas FB et al. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 2005; 111: 629-632.
49. Eitzman DT, Bodary PF, Shen Y et al. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 2003; 14: 298-302.
50. Hiraoka M, Abe A, Shayman JA. Structure and function of lysosomal phospholipase A2: identification of the catalytic triad and the role of cysteine residues. J Lipid Res 2005; 46: 2441-2447.
51. Hiraoka M, Abe A, Shayman JA. Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. J Biol Chem 2002; 277: 10090-10099.
52. Nisoli E, Falcone S, Tonello C et al. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci USA 2004; 101: 16507-16512.
53. Clementi E, Nisoli E. Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism. Comp Biochem Physiol A 2005; 142: 102-110.
54. Nisoli E, Clementi E, Paolucci C et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003; 299: 896-899.
55. Marciniak SJ, Garcia-Bonilla L, Hu J et al. Activation-dependent substrate recruitment by the eukaryotic translation initiation factor 2 kinase PERK. J Cell Biol 2006; 172: 201-209.
56. Silva RM, Ries V, Oo TF et al. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem 2005; 95: 974-986.
57. Marciniak SJ, Yun CY, Oyadomari S et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 2004; 18: 3066-3077.
58. Michaelis UR, Fisslthaler B, Barbosa-Sicard E et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 2005; 118(Part 23): 5489-5498.
59. Michaelis UR, Fisslthaler B, Medhora M et al. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 2003; 17: 770-772.
60. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005; 289: F496-F503.
61. Zhao X, Yamamoto T, Newman JW et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004; 15: 1244-1253.
62. Zhang F, Deng H, Kemp R et al. Decreased levels of cytochrome P450 2E1-derived eicosanoids sensitize renal arteries to constrictor agonists in spontaneously hypertensive rats. Hypertension 2005; 45: 103-108.
63. Li P, Jiang H, Yang L et al. Angiotensin II induces carbon monoxide production in the perfused kidney: relationship to protein kinase C activation. Am J Physiol Renal Physiol 2004; 287: F914-F920.
64. Kaide J, Zhang F, Wei Y et al. Vascular CO counterbalances the sensitizing influence of 20-HETE on agonist-induced vasoconstriction. Hypertension 2004; 44: 210-216.
65. Kawada N, Dennehy K, Solis G et al. TP receptors regulate renal hemodynamics during angiotensin II slow pressor response. Am J Physiol Renal Physiol 2004; 287: F753-F759.
66. Wang D, Chabrashvili T, Wilcox CS. Enhanced contractility of renal afferent arterioles from angiotensin-infused rabbits: roles of oxidative stress, thromboxane prostanoid receptors, and endothelium. Circ Res 2004; 94: 1436-1442.
67. Sanchez-Lozada LG, Nakagawa T, Kang DH et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens 2006; 15: 30-33.
68. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562.
69. Nakagawa T, Hu H, Zharikov S et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290: F625-F631.
70. Feig D, Mazzali M, Kang DH et al. Serum uric Acid: a risk factor and a target for treatment? J Am Soc Nephrol 2006; 17(Suppl 2): S69-S73.
71. de Jager J, Dekker JM, Kooy A et al. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with Type 2 diabetes. The Hoorn Study. Arterioscler Thromb Vasc Biol 2006; 26: 1086-1093.
72. Stam F, Van Guldener C, Becker A et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006; 17: 537-545.
73. Ijzerman RG, Voordouw JJ, Van Weissenbruch MM et al. TNF-alpha levels are associated with skin capillary recruitment in humans: a potential explanation for the relationship between TNF-alpha and insulin resistance. Clin Sci (London) 2006; 110: 361-368.
74. Radomski A, Jurasz P, Alonso-Escolano D et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 2005; 146: 882-893.
75. Alonso D, Radomski MW. Nitric oxide, platelet function, myocardial infarction and reperfusion therapies. Heart Fail Rev 2003; 8: 47-54.
76. Sandow SL. Factors, fiction and endothelium-derived hyperpolarizing factor. Clin Exp Parmacol Physiol 2004; 31: 563-570.
77. Reville K, Crean JK, Vivers S et al. Lipoxin A4 redistributes myosin NA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J Immunol 2006; 176: 1878-1888.
78. Rodgers K, McMahon B, Mitchell D et al. Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am J Pathol 2005; 167: 683-694.
79. Eremina V, Quaggin SE. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004; 13: 9-15.
80. Yilmaz M, Saglam M, Caglar K et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006; 47: 42-50.
81. Ravani P, Tripepi G, Malberi F et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risk modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455.
82. van Zonneveld AJ, Rabelink TJ. Endothelial progenitor cells: biology and therapeutic potential in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 167-172.
83. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006; 17: 932-942.
84. Rabelink TJ, Luscher TF. Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol 2006; 26: 267-271.
85. Woywodt A, Goldberg C, Kirsch T et al. Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis. Ann Rheum Dis 2006; 65: 164-168.
86. Woywodt A, Bahlmann FH, De Groot K et al. Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer. Nephrol Dial Transplant 2002; 17: 1728-1730.
87. Deanfield J, Donald A, Ferri C et al. Endothelial function and dysfunction. Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society for Hypertension. J Hypertens 2005; 23: 7-17.
88. Stewart J, Kohen A, Brouder D et al. Noninvasive interrogation of microvasculature for signs of endothelial dysfunction in patients with chronic renal failure. Am J Physiol Heart Circ Physiol 2004; 287: H2687-H2696.
89. Guerin A, Pannier B, Marchais S, London G. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Curr Opinion Nephrol Hypertens 2006; 15: 105-110.